Podium to Practice: EHA 2026 – Leukemia: Reduced-Duration Venetoclax in AML
OR
Studies / Trials Discussed
S129 – PROSPECTIVE NAMLG LD-VENEX TRIAL: AZACITIDINE IN COMBINATION WITH REDUCED DURATION OF VENETOCLAX IN PATIENTS WITH DE NOVO, SECONDARY, AND RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Chair
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
S129 – PROSPECTIVE NAMLG LD-VENEX TRIAL: AZACITIDINE IN COMBINATION WITH REDUCED DURATION OF VENETOCLAX IN PATIENTS WITH DE NOVO, SECONDARY, AND RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.